ATHE Profile
Alterity Therapeutics Limited is an Australian biotechnology company focused on the research and development of innovative therapeutic drugs for a range of neurological disorders. The company is dedicated to addressing complex diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease through its advanced drug development programs. Alterity's approach integrates cutting-edge science and clinical research to create targeted treatments for these challenging conditions.
One of the company's primary drug candidates is ATH434, which has successfully completed Phase I clinical trials for the treatment of Parkinson's disease. ATH434 represents a promising advancement in the field, aiming to address the underlying mechanisms of Parkinson's and offer new therapeutic options for patients. In addition, Alterity is advancing PBT2, another key candidate that has completed Phase 2a clinical trials for Alzheimer's disease. PBT2 is designed to target and modify disease pathways, potentially providing significant benefits for individuals with Alzheimer's.
Alterity Therapeutics Limited was formerly known as Prana Biotechnology Limited and underwent a rebranding to its current name in April 2019 to better reflect its strategic focus and evolving research priorities. Founded in 1997, the company is headquartered in Melbourne, Australia, and operates with a strong commitment to advancing neurological disease treatments through rigorous scientific research and clinical development.
As Alterity Therapeutics progresses with its clinical trials and research initiatives, it remains at the forefront of developing novel therapies for neurodegenerative diseases. The company’s dedication to innovation and patient-centric solutions underscores its mission to address significant unmet medical needs and improve the quality of life for individuals affected by these debilitating conditions. With a robust pipeline and strategic focus, Alterity Therapeutics is well-positioned to make substantial contributions to the field of neurology and therapeutic development.
|
